Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biomarin Pharmaceut (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,547,638
  • Shares Outstanding, K 175,620
  • Annual Sales, $ 1,117 M
  • Annual Income, $ -630,210 K
  • 36-Month Beta 1.82
  • Price/Sales 13.94
  • Price/Cash Flow N/A
  • Price/Book 5.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.10 +16.13%
on 12/06/17
93.02 unch
on 12/15/17
+11.21 (+13.70%)
since 11/15/17
3-Month
80.10 +16.13%
on 12/06/17
96.05 -3.15%
on 10/16/17
+1.11 (+1.21%)
since 09/15/17
52-Week
80.10 +16.13%
on 12/06/17
100.51 -7.45%
on 05/05/17
+7.67 (+8.99%)
since 12/15/16

Most Recent Stories

More News
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

CORT : 16.61 (-3.82%)
ONCE : 46.37 (+2.57%)
BMRN : 93.02 (+5.07%)
PFE : 37.20 (+2.03%)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%

BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EBS : 46.80 (+1.10%)
BMRN : 93.02 (+5.07%)
Today's Research Reports on Stocks to Watch: bluebird bio and BioMarin Pharmaceutical

NEW YORK, NY / ACCESSWIRE / December 12, 2017 / Shares of bluebird headed to record highs after announcing positive results on its Sickle Cell disease treatment LentiGlobin. Shares also retraced shortly...

BLUE : 182.95 (-0.76%)
BMRN : 93.02 (+5.07%)
BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH.

BMRN : 93.02 (+5.07%)
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

JNJ : 142.46 (+0.57%)
MRK : 56.24 (+0.41%)
VRTX : 145.86 (+2.34%)
BMRN : 93.02 (+5.07%)
INCY : 96.41 (+0.46%)
PFE : 37.20 (+2.03%)
ALXN : 115.76 (+2.36%)
BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational...

BMRN : 93.02 (+5.07%)
BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition...

BMRN : 93.02 (+5.07%)
Here's Why Sarepta Stock is Up More Than 70% in 6 Months

Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

CORT : 16.61 (-3.82%)
SRPT : 52.60 (-1.96%)
AGN : 171.68 (+0.43%)
BMRN : 93.02 (+5.07%)
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

LGND : 135.87 (-0.12%)
SCMP : 17.00 (+1.49%)
BMRN : 93.02 (+5.07%)
CPRX : 4.08 (-0.49%)
BioMarin Sells Second Priority Review Voucher for $125 Million

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in April of this...

BMRN : 93.02 (+5.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

2nd Resistance Point 96.03
1st Resistance Point 94.53
Last Price 93.02
1st Support Level 90.01
2nd Support Level 86.99

See More

52-Week High 100.51
Last Price 93.02
Fibonacci 61.8% 92.71
Fibonacci 50% 90.31
Fibonacci 38.2% 87.90
52-Week Low 80.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.